BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 17050654)

  • 1. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure.
    Nutt D; Demyttenaere K; Janka Z; Aarre T; Bourin M; Canonico PL; Carrasco JL; Stahl S
    J Psychopharmacol; 2007 Jul; 21(5):461-71. PubMed ID: 17050654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression.
    Trivedi MH; Hollander E; Nutt D; Blier P
    J Clin Psychiatry; 2008 Feb; 69(2):246-58. PubMed ID: 18363453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effectiveness of antidepressants in the treatment of chronic non-cancer pain--a review].
    Miller A; Rabe-Jabłońska J
    Psychiatr Pol; 2005; 39(1):21-32. PubMed ID: 15771151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
    Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
    J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
    Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
    Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role for a pure noradrenergic drug in the treatment of depression?
    Montgomery SA
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S3-9; discussion S71-3. PubMed ID: 9169305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in mechanism of action between current and future antidepressants.
    Stahl SM; Grady MM
    J Clin Psychiatry; 2003; 64 Suppl 13():13-7. PubMed ID: 14552651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of antidepressants: selectivity or multiplicity?
    Westenberg HG
    J Clin Psychiatry; 1999; 60 Suppl 17():4-8; discussion 46-8. PubMed ID: 10446734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual-action hypothesis: does pharmacology matter?
    Shelton RC
    J Clin Psychiatry; 2004; 65 Suppl 17():5-10. PubMed ID: 15600376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
    Lane RM
    J Psychopharmacol; 2015 May; 29(5):526-44. PubMed ID: 25315829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological principles of antidepressant efficacy.
    Schatzberg AF
    Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S17-22. PubMed ID: 12404665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
    Prins J; Olivier B; Korte SM
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1107-30. PubMed ID: 21682663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
    Millan MJ
    Pharmacol Ther; 2006 May; 110(2):135-370. PubMed ID: 16522330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norepinephrine involvement in antidepressant action.
    Frazer A
    J Clin Psychiatry; 2000; 61 Suppl 10():25-30. PubMed ID: 10910014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects.
    Dell'Osso B; Palazzo MC; Oldani L; Altamura AC
    CNS Neurosci Ther; 2011 Dec; 17(6):723-32. PubMed ID: 21155988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine dysfunction and the pathophysiology and treatment of depression.
    Charney DS
    J Clin Psychiatry; 1998; 59 Suppl 14():11-4. PubMed ID: 9818625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.